[Chronic Kidney Disease and SGLT2 Inhibitors: Single Center Experience].

Abstract

Chronic kidney disease is a very common condition, often underdiagnosed, and a major risk factor for cardiovascular complications and premature death. There is an increasing interest in scientific society in implementing effective treatments for kidney disease to slow progression. In the last decades angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been the only drugs recommended for chronic kidney disease. More recently a further therapeutic choice has been developed: SGLT2 inhibitors. We present a single center observational study aimed at understanding the efficacy and safety of Dapaglifozin in nephropathic population. The trial started in February 2023, and concluded in June 2024. We collected blood tests monthly and one urine sample for urinecolture in the first month, afterwards only in case of disuric symptoms. We enrolled 21 diabetic patients and 7 nondiabetic patients. They were all receiving a maximum tolerated dose of renin-angiotensin system at enrolment.